SNORD108: A Small Nucleolar RNA as a Drug Target and Biomarker

Target Name: SNORD108

NCBI ID: G338427

SNORD108

Other Name(s): small nucleolar RNA, C/D box 108 | HBII-437 | Small nucleolar RNA, C/D box 108

SNORD108: A Small Nucleolar RNA as a Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is SNORD108, which is expressed in high levels in various tissues and cell types. Although SNORD108 has been extensively studied for its role in gene regulation, its potential as a drug target or biomarker remains unexplored. In this article, we will explore the potential of SNORD108 as a drug target and biomarker.

Drug Target Potential

SNORD108 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. SNORD108 is a C/D box snRNA that contains a unique fMetbox gene that is located at the 5' end of the RNA molecule. The fMetbox gene is a known regulator of protein synthesis and has been implicated in various cellular processes, including cell growth, apoptosis, and translation of RNA molecules.

One of the key advantages of SNORD108 as a drug target is its high human expression. SNORD108 is expressed in various tissues and cell types, including brain, heart, liver, and muscle. Additionally, its expression is highly correlated with the expression of other genes that are involved in cellular processes, such as cell growth, apoptosis, and translation of RNA molecules. This suggests that targeting SNORD108 may have potential benefits for various diseases.

Biomarker Potential

SNORD108 has also been identified as a potential biomarker due to its unique expression patterns. The expression of SNORD108 is highly correlated with the expression of other genes that are involved in cellular processes, such as cell growth, apoptosis, and translation of RNA molecules. Additionally, its expression is highly correlated with the expression of genes that are involved in cancer, such as the expression of the oncogene transforming growth factor-尾 (TGF-β).

This suggests that SNORD108 may be a useful biomarker for various diseases, including cancer. Further studies are needed to confirm its potential as a biomarker and to explore its potential as a drug target.

Conclusion

In conclusion, SNORD108 is a unique small nucleolar RNA that has been extensively studied for its role in gene regulation. Its high human expression and its involvement in various cellular processes make it a potential drug target. Additionally, its unique expression patterns suggest that it may be a useful biomarker for various diseases, including cancer. Further studies are needed to confirm its potential as a drug target and to explore its potential as a biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 108

The "SNORD108 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD108 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets